Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 6Expanded_access 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × lifileucel × Clear all
NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Iovance Biotherapeutics, Inc.

Available
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡